Shawn Kwatra, MD

Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

Shawn Kwatra, MD, shares insights into neuropathic pruritus’ debilitating effects on patients and how clinicians can use unified nomenclature.

An expert in dermatology reviews the case of a 33-year-old male patient suffering from atopic dermatitis for the past 3 years. He breaks down the panel's conversation on the use of non-steroidal topicals and emphasizes how patient assistance programs can ease burden for patients and providers.

Shawn Kwatra, MD, presents a case involving a 73-year-old African American female seeking treatment for her atopic dermatitis. In this segment Dr Kwatra explains the panels thoughts and rationale behind the prescribed treatments, discussing how each option works and its limitations.

Kwatra presented on the unmet need for itch improvement in patients with skin of color.

Shawn Kwatra, MD, shares his thoughts on the positive phase 3 data of OLYMPIA 2.

Kwatra discussed his research team’s findings published in JAMA Dermatology.

Kwatra reviewed skin lesions in PN and important treatment considerations for patients at Fall Clinical.

Kwatra presented the abrocitinib data at EADV 2023.

To further discuss the changing landscape of skin of color representation in dermatology, Christopher Bunick, MD, PhD, and Shawn Kwatra, MD, review how they have seen representation change in their own experiences.

Experts discuss prospective therapies on the horizon for atopic dermatitis (AD).

Experts offer their clinical experience on preventing patient withdrawal and breaking the atopic dermatitis (AD) disease cycle.

Peter Lio, MD, FAAD, discusses how body surface area of atopic dermatitis (AD) affects topical treatment options.

Shawn Kwatra, MD, offers important considerations for providers when utilizing topical therapies for atopic dermatitis (AD).

Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).

Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).

Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.

Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.